Sanofi pasteur Supports WHO Initiative for the Establishment of an H5N1 Vaccine Stockpile

    Sanofi pasteur Continues to Commit Resources and Join the International
    Community in Enhancing Pandemic Preparedness to Protect World Health

    LYON, France, June 13 /CNW/ - Sanofi pasteur, the vaccines division of
the sanofi-aventis Group, announced today that it is ready to supply a
significant number of doses of H5N1 vaccine for the establishment of an
international stockpile through a World Health Organization (WHO) partnership.
Part of this supply could be made available immediately, in bulk form.
    "We have been part of the influenza vaccine history for half of a century
and are pleased today to continue to partner with WHO to combat one of the
world's critical public health threats" said Jean-Francois Dehecq, Chairman of
sanofi-aventis. "Above and beyond this vital initiative with the international
community and with WHO, we are actively pursuing further moves that are
intended to increase influenza vaccine supply for countries in the developing
world, enabling us to provide a meaningful contribution to global pandemic
    Sanofi pasteur's leadership position in developing and producing
influenza vaccines places the company at the forefront of readiness against
the threat of pandemic influenza. The company is committed to playing a
leading role in case of a pandemic and sees its contribution in producing as
many doses of sanofi pasteur's most advanced vaccine in the shortest possible
timeframe, should a pandemic be declared by the world's health authorities.

    Pandemic Influenza Overview

    Influenza is a disease caused by a highly infectious virus that spreads
easily from person to person, primarily when an infected individual coughs or
sneezes. An influenza pandemic is a global epidemic of an especially virulent
virus, newly infectious for humans, and for which there is no preexisting
immunity. This is why pandemic strains have such potential to cause severe
morbidity and mortality. According to the World Health Organization (WHO), the
next pandemic is likely to result in 1 to 2.3 million hospitalizations and
280,000 to 650,000 deaths in industrialized nations alone. Its impact is
expected to be even more devastating in developing countries. In an attempt to
minimize the impact of a pandemic, many countries are developing national and
transnational plans against a possible influenza pandemic situation.

    Sanofi Pasteur and Pandemic Preparedness

    Sanofi pasteur is committed to global pandemic preparedness. As the world
leader in research, development and manufacturing of influenza vaccine, sanofi
pasteur is actively involved in projects in the U.S. and Europe, with the goal
of developing a vaccine to protect against a pandemic influenza virus.
    Sanofi pasteur is also investing in major expansions of its influenza
vaccine production facilities in the U.S. and France.
    For more information please visit

    About sanofi-aventis

    Sanofi-aventis is one of the world leaders in the pharmaceutical
industry, ranking number one in Europe. Backed by a world-class R&D
organisation, sanofi-aventis is developing leading positions in seven major
therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases,
central nervous system, internal medicine and vaccines. Sanofi-aventis is
listed in Paris (EURONEXT: SAN) and in New York (NYSE:   SNY).

    Sanofi pasteur, the vaccines division of the sanofi-aventis Group,
provided more than a billion doses of vaccine in 2006, making it possible to
immunize more than 500 million people across the globe. A world leader in the
vaccine industry, sanofi pasteur offers the broadest range of vaccines
protecting against 20 infectious diseases. The Company's heritage, to create
vaccines that protect life, dates back more than a century. Sanofi pasteur is
the largest company entirely dedicated to vaccines. Every day, the company
invests more than EUR1 million in research and development. For more
information, please visit: or

    Forward Looking Statements

    This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include financial projections and estimates and their underlying assumptions,
statements regarding plans, objectives, intentions and expectations with
respect to future events, operations, products and services, and statements
regarding future performance. Forward-looking statements are generally
identified by the words "expects," "anticipates," "believes," "intends,"
"estimates," "plans" and similar expressions. Although sanofi-aventis'
management believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and uncertainties,
many of which are difficult to predict and generally beyond the control of
sanofi-aventis, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include those discussed or identified in the public filings with the SEC and
the AMF made by sanofi-aventis, including those listed under "Risk Factors"
and "Cautionary Statement Regarding Forward-Looking Statements" in
sanofi-aventis' annual report on Form 20-F for the year ended December 31,
2006. Other than as required by applicable law, sanofi-aventis does not
undertake any obligation to update or revise any forward-looking information
or statements.

For further information:

For further information: sanofi pasteur: Pascal Barollier, International
Media Relations, Tel: +33-(0)4-37-37-51-41,; sanofi pasteur: Len Lavenda, U.S. Media
Relations, Tel: (570) 839-4446,

Organization Profile

Sanofi Pasteur

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890